RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai’s Brii Bioscience will have China rights to as many as three infectious disease candidates developed by Artizan Biosciences, a spin-out from Yale University. Brii participated in a Series A funding that brought Artizan’s total funds raised to $12 million, though Brii’s financial commitment to the round was not disclosed. Artizan is developing intestinal microbiota candidates for inflammatory diseases including its lead candidate, a treatment for Inflammatory Bowel Disease (IBD). Artizan uses its IgA-SEQ™ technology platform to identify disease-driving bacteria contained in human intestinal microbiota.
Source: China Biotoday
